Navigating the complexities of mergers, acquisitions, and regulatory compliance demands experienced and reliable partners. At income-partners.net, we understand the critical role of Trustee Partners in ensuring adherence to regulatory requirements and facilitating smooth business transitions. Monitoring Trustee Partners B.V. (“MTP”) stands as a global leader in providing monitoring trustee and divestiture trustee services, offering unparalleled expertise to businesses worldwide.
MTP’s team boasts a remarkable track record, having successfully managed over 65 cases related to mergers, market dominance, and state aid across diverse industries. Their portfolio spans pharmaceuticals, chemicals, energy, food and beverages, financial services, manufacturing, and transportation, showcasing their adaptability and comprehensive industry knowledge. Working alongside numerous multinational corporations, MTP has cultivated extensive experience in handling a wide spectrum of structural and behavioral remedies. This includes significant involvement in intricate M&A and carve-out projects, underscored by the preparation of over 85 purchaser approval reports.
What sets MTP apart as premier trustee partners is their unique blend of trustee-specific knowledge, industry insight, engineering proficiency, local market understanding, and legal acumen. The core team comprises individuals with distinguished backgrounds in corporate finance, banking, and law, originating from reputable firms such as Arthur Andersen, BNP Paribas, Capgemini Consulting, Duff & Phelps, EY, Landesbank Berlin, Peacock & Co, PwC, Société Générale, and Standard & Poor’s. Notably, a member of their core team has also contributed directly to regulatory oversight, having served with the European Commission during the financial crisis, assisting with state aid evaluations.
Selected credentials can be found here.
MTP’s recent engagements highlight their active role in significant global cases:
- Broadcom / VMware – SAMR (China)
- Teva USA – No. 2:20-cr-200 DOJ (United States)
- Novozymes / Chr Hansen – M.11043 EC
- Hitachi / Thales – M.10507 EC and ME/6971/21CMA (UK)
- Advent / GfK – M.10860 EC
- Medivet / multiple veterinary businesses – ME/7022/22 CMA (UK)
- II-VI Incorporated / Coherent – SAMR (China)
- Celanese / DuPont Mobility & Materials – M.10721 EC
- Cellnex / CK Hutchison UK towers – ME/6917/20 CMA (UK)
- Ali Group / Welbilt – M.10431 EC
- Plus / Coop – 21/053545 ACM (NL)
- S&P / IHSM – CCB (CA), CMA (UK), M.10108 EC
- eBay / Adevinta – Z-5420 BWB (AT)
- Aon / WTW – M. 9829 EC
- TUI – SA.59812 EC
- Mastercard / Nets – M.9744 EC
- Uber / Careem – CCP (PK)
- Elanco / Bayer Animal Health – M.9554 EC
- AbbVie / Allergan – M.9461 EC
- Knauf / USG – ACCC (AU), NZCC (NZ)
These case examples underscore MTP’s capability in managing complex, multi-jurisdictional scenarios. Below are further details on select engagements:
S&P / IHSM – CCB (CA), CMA (UK), M.10108 EC
In S&P’s USD 44 billion acquisition of IHSM, MTP acted as trustee partners, monitoring the divestiture of four distinct business units on behalf of the Canadian Competition Bureau (CCB), the UK Competition and Markets Authority (CMA), and the European Commission. This complex undertaking involved overseeing four hold-separate managers and navigating the intricate disentanglement of shared customer contracts. The divestment businesses were ultimately acquired by FactSet, Morningstar, and News Corporation.
Elanco / Bayer Animal Health M.9554 EC
For Elanco’s USD 7.6 billion acquisition of Bayer Animal Health, the European Commission appointed MTP as trustee partners to monitor the sale process of four divestment businesses. This included ensuring the ring-fencing and viability of several animal health pipeline and on-market products. The project required the involvement of three hold-separate managers and four purchaser approvals, with Dechra, MSD, Vetoquinol, and Virbac acquiring the divestment businesses.
Teva / Allergan Generics M.7746 EC
During Teva’s USD 39.6 billion acquisition of Allergan Generics, MTP served as trustee partners, mandated by the European Commission to oversee a significant remedy package divestiture. This encompassed 10 divestment businesses, including over 650 generics products across 26 EEA countries, a UK-based manufacturing plant, and behavioral commitments. The process involved three hold-separate managers and seven purchaser approvals, with purchasers including Alvogen, Aurobindo, and Intas/Accord Healthcare.
Maersk Line / Hamburg Süd M.8330 EC / FNE (CL) / SAMR (CN)
In Maersk Line’s EUR 3.7 billion acquisition of Hamburg Süd, MTP acted as trustee partners for the European Commission, the Fiscalía Nacional Económica (FNE, Chile), and the Ministry of Commerce People’s Republic of China (SAMR, China). Their role was to monitor Maersk Line’s compliance with behavioral commitments related to container shipping trades across Europe, the Americas, and Asia.
ChemChina / Syngenta M.7962 EC / CCI (IN)/ FTC (US)
For ChemChina’s USD 43 billion acquisition of Syngenta, MTP functioned as trustee partners, monitoring the divestiture of a broad agrochemical product portfolio across multiple jurisdictions for the European Commission, the FTC (United States), and the Competition Commission of India (CCI, India). This involved sales to Amvac and Nufarm and overseeing the execution of specific behavioral commitments.
If you require further information about MTP and how their expertise as trustee partners can benefit your company, please reach out to them at + 31 20 210 5270 or via email at [email protected]. Let MTP be your trusted guide in navigating regulatory landscapes and ensuring successful business outcomes.
